Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Feb;40(2):365-373.
doi: 10.1177/0271678X18820765. Epub 2018 Dec 20.

Parametric methods for [18F]flortaucipir PET

Affiliations
Clinical Trial

Parametric methods for [18F]flortaucipir PET

Sandeep Sv Golla et al. J Cereb Blood Flow Metab. 2020 Feb.

Abstract

[18F]Flortaucipir is a PET tau tracer used to visualize tau binding in Alzheimer's disease (AD) in vivo. The present study evaluated the performance of several methods to obtain parametric images of [18F]flortaucipir. One hundred and thirty minutes dynamic PET scans were performed in 10 AD patients and 10 controls. Parametric images were generated using different linearization and basis function approaches. Regional binding potential (BPND) and volume of distribution (VT) values obtained from the parametric images were compared with corresponding values derived using the reversible two-tissue compartment model (2T4k_VB). Performance of SUVr parametric images was assessed by comparing values with distribution volume ratio (DVR) and SRTM-derived BPND estimates obtained using non-linear regression (NLR). Spectral analysis (SA) (r2 = 0.92; slope = 0.99) derived VT correlated well with NLR-derived VT. RPM (r2 = 0.95; slope = 0.98) derived BPND correlated well with NLR-derived DVR. Although SUVr80-100 min correlated well with NLR-derived DVR (r2 = 0.91; slope = 1.09), bias in SUVr appeared to depend on uptake time and underlying level of specific binding. In conclusion, RPM and SA provide parametric images comparable to the NLR estimates. Individual SUVr values are biased compared with DVR and this bias requires further study in a larger dataset in order to understand its consequences.

Keywords: AV-1451; Alzheimer’s disease; [18F]flortaucipir; parametric imaging; tau imaging.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(a) Logan- and SA-derived VT parametric images for a representative AD patient and a control. Correlation for (b) Logan and (c) SA VT values with corresponding NLR estimates. LOI is line of identity. AD: Alzheimer’s disease; NLR: non-linear regression; SA: spectral analysis.
Figure 2.
Figure 2.
(a) RLogan-, RPM- and SRTM2-derived DVR/BPND parametric images for a representative AD patient and a control. Correlations for (b) RPM, (c) SRTM2 and (d) RLogan DVR/BPND values with corresponding NLR estimates. LOI is line of identity. AD: Alzheimer’s disease; BPND: binding potential; DVR-1: distribution volume ratio; NLR: non-linear regression; RLogan: reference Logan; RPM: receptor parametric mapping; SRTM2: simplified reference tissue model 2.
Figure 3.
Figure 3.
SUVr-1 images of an AD patient for different time intervals. BPND images obtained using RLogan, RPM and SRTM2 are also shown as reference for specific binding. BPND: binding potential; DVR-1: distribution volume ratio; RLogan: reference Logan; RPM: receptor parametric mapping; SRTM2: simplified reference tissue model 2; SUVr-1: standard uptake value ratio.
Figure 4.
Figure 4.
SUVr-1 images of a control for different time intervals. BPND images obtained using RLogan, RPM and SRTM2 are also shown as reference for specific binding. BPND: binding potential; DVR-1: distribution volume ratio; RLogan: reference Logan; RPM: receptor parametric mapping; SRTM2: simplified reference tissue model 2; SUVr-1: standard uptake value ratio.
Figure 5.
Figure 5.
Bar plots of % bias (mean ± SD) observed in SUVr with respect to the NLR-estimated DVR (BPND + 1) for different SUVr time intervals for all the grey matter VOIs from hammers template. AD: Alzheimer’s disease; SUVr: standard uptake value ratio.

References

    1. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 2009; 68: 1–14. - PMC - PubMed
    1. Chien DT, Bahri S, Szardenings AK, et al.Early clinical PET imaging results with the novel PHF-Tau Radioligand [F-18]-T807. J Alzheimers Dis 2013; 34: 457–468. - PubMed
    1. Marquie M, Normandin MD, Vanderburg CR, et al.Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015; 78: 787–800. - PMC - PubMed
    1. Lowe VJ, Curran G, Fang P, et al.An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 2016; 4: 58. - PMC - PubMed
    1. Sander K, Lashley T, Gami P, et al.Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement 2016; 12: 1116–1124. - PubMed

Publication types